FFF Enterprises: BioSupply Trends Newsletter
Monday, November 20, 2017

CDC Recommends Shingrix Vaccine to Prevent Shingles

 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

One day after the U.S. Food and Drug Administration approved Shringrix to prevent shingles (herpes zoster) in patients 50 years and older, the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommended the use of Shingrix to prevent shingles over Merck’s Zostavax vaccine that is less effective, but was the only shingles vaccine on the market for over a decade. ACIP also recommended that adults who have received the older vaccine get the new one. [ read more ]

Study Shows Impact of Age and Pre-Existing Influenza Immune Responses in Older and Younger Adults

In an effort to understand how current influenza vaccines are influenced by pre-existing immunity in people of different ages, researchers vaccinated volunteers ages 18 years to 85 years with split, inactivated Fluzone influenza vaccine in four consecutive seasons from 2013 to 2016, and assessed the impact of repeated vaccination on breadth and durability of antibodies as a result of vaccine strain changes. They found that, overall, both younger and older people have the ability to mount a breadth of immune responses following influenza vaccination. [ read more ]

Subcutaneous Immune Globulin Is Well-Tolerated and Effective in Mild to Moderate Exacerbations of Myasthenia Gravis

A study at the University of Alberta, Canada, found that subcutaneous immune globulin treatment is well-tolerated, safe and effective in mild to moderate myasthenia gravis exacerbations, but acknowledged that “comparative safety and efficacy must be established with randomized controlled trials.” [ read more ]

Industry News

 
 

From CSL Behring

CSL Behring has awarded three U.S. bleeding disorder patient organizations Local Empowerment for Advocacy Development (LEAD) grants to help them ensure patients’ voices continue to be heard in their state capitals on legislative and public policy issues. [ read more ]

From Roche

The U.S. Food and Drug Administration has approved Roche's Zika screening test, which is designed as a qualitative in-vitro nucleic acid screening indication to directly detect the RNA in plasma samples of individual blood donors.  [ read more ]

From Shire

Shire has been awarded orphan drug designation by the U.S. Food and Drug Administration for its gene therapy candidate SHP654 (also designated as BAX 888), an investigational factor VIII gene therapy for the treatment of hemophilia A. [ read more ]

IVIG & Albumin Supply Index

 
 

What's New at FFF

PANTOPRAZOLE SODIUM (AUROMEDICS PHARMA LLC)

PANTOPRAZOLE SODIUM (injection) is a proton pump inhibitor indicated for 1) short-term treatment (seven to 10 days) of gastroesophageal reflux disease associated with a history of erosive esophagitis and 2) pathological hypersecretion conditions, including Zollinger-Ellison syndrome. It is supplied in 40 mg pantoprazole freeze-dried powder in a single-dose vial for reconstitution.

For more information about PANTOPRAZOLE SODIUM,
login to biosupply.fffenterprises.com

These products are available thru FFF Enterprises’ BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective Oct. 1, 2017, through Dec. 31, 2017.

Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Carimune NF J1566 $68.56 $67.46
Flebogamma J1572 $59.67 $58.71
Gammagard S/D J1566 $68.56 $67.46
Gammaplex J1557 $82.16 $80.84
Octagam J1568 $73.24 $72.06
Privigen J1459 $77.01 $75.78
SCIG
CUVITRU ** J3490/J3590/J7799 - -
Hizentra J1559 $98.13 $96.56
HyQvia J1575 $131.36 $129.25
IVIG / SCIG
Gammagard Liquid J1569 $79.57 $78.29
Gammaked J1561 $77.89 $76.64
Gamunex-C J1561 $77.89 $76.64

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.

 

Resources

FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2017 FFF Enterprises, Inc.
This email was sent by: %%Member_Busname%%, %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
Manage preferences: Privacy Policy, Update Profile, Unsubscribe.